Skip to main content
SpringerLink
Log in

Clinical Implications of Soft Tissue Sarcomas

  • Chapter
  • First Online:
Imaging in Clinical Oncology

  • 1635 Accesses

Abstract

The therapeutic strategy depends on disease stage at baseline, tumor grade, and histological subtype. Ultrasounds, plain X-rays, CT and MRI scans, angiography, and bone scans are the main diagnostic tools used in the diagnosis and staging of the disease [1].

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 189.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 249.00
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 249.00
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  1. Panicek DM, Gatsonis C, Rosenthal DI et al (1997) CT and MR imaging in the local staging of primary malignant musculoskeletal neoplasms: report of the Radiology Diagnostic Oncology Group. Radiology 202:237–246

    Article  CAS  Google Scholar 

  2. Noebauer-Huhmann IM, Weber MA, Bloem JL et al (2015) Soft tissue tumors in adults: ESSR-approved guidelines for diagnostic imaging. Semin Musculoskelet Radiol 19(5):475–482

    Article  Google Scholar 

  3. Rizer M, Singer AD, Subhawong TK et al (2016) The histological variants of liposarcoma: predictive MRI findings with prognostic implications, management, follow-up, and differential diagnosis. Skelet Radiol 45(9):1193–1204

    Article  Google Scholar 

  4. Scola D, Bahoura L, Copelan A, Sokhandon F (2017) Getting the GIST: a pictorial review of the various patterns of presentation of gastrointestinal stromal tumors on imaging. Abdom Radiol (NY) 42(5):1350–1364. https://doi.org/10.1007/s00261-016-1025-z

    Article  Google Scholar 

  5. ESMO/European Sarcoma Network Working Group (2014) Soft tissue and visceral sarcomas: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol (Suppl 3):iii102–iii112

    Google Scholar 

  6. ESMO/European Sarcoma Network Working Group (2014) Bone sarcomas: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol (Suppl 3):iii113–iii123

    Google Scholar 

  7. Crim JR, Seeger LL, Yao L et al (1992) Diagnosis of soft tissue masses with MR imaging: can benign masses be differentiated from malignant ones. Radiology 185:581–586

    Article  CAS  Google Scholar 

  8. Rimondi E, Benassi M, Vanel D et al (2016) Translational research in diagnosis and management of soft tissue tumours. Cancer Imaging 16:13

    Article  Google Scholar 

  9. Etchebehere EC et al (2015) Assessing the role of 18F-FDG PET and 18F-FDG PET/CT in the diagnosis of soft tissue musculoskeletal malignancies—a systematic review and meta-analysis. Eur J Nucl Med Mol Imaging 43(5):860–870

    Article  Google Scholar 

  10. Fisher SM, Joodi R, Chhabra A et al (2016) Current utilities of imaging in grading musculoskeletal soft tissue sarcomas. Eur J Radiol 85(7):1336–1344

    Article  Google Scholar 

  11. Eisenhauer EA, Therasse P, Bogaerts J et al (2009) New response evaluation criteria in solid tumors: revised RECIST guideline (version 1.1). Eur J Cancer 45:228–247

    Article  CAS  Google Scholar 

  12. Michaelis LC, Ratain MJ (2006) Measuring response in a post-RECIST world: from black and white to shades of grey. Nat Rev Cancer 6:409–414

    Article  CAS  Google Scholar 

  13. Baheti AD, Jagannathan JP, Tirumani SH et al (2017) Current concepts in non-gastrointestinal stromal tumor soft tissue sarcomas: a primer for radiologists. Korean J Radiol 18(1):94–106

    Article  Google Scholar 

  14. Blanke C, Demetri G, von Mehren M et al (2008) Long-term results from a randomized phase II trial of standard-versus higher-dose imatinib mesylate for patients with unresectable or metastatic gastrointestinal stromal tumors expressing KIT. J Clin Oncol 26(4):620–625

    Article  CAS  Google Scholar 

  15. Dhani N, Tu D, Sargent DJ, Seymour L et al (2009) Alternate endpoints for screening phase II studies. Clin Cancer Res 15:1873–1882

    Article  CAS  Google Scholar 

  16. ESMO/European Sarcoma Network Working Group (2014) Gastrointestinal stromal tumours: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol (Suppl 3):iii21–iii26

    Google Scholar 

  17. Kalkmann J, Zeile M, Stattaus J et al (2012) Consensus report on the radiological management of patients with gastrointestinal stromal tumours (GIST): recommendations of the German GIST Imaging Working Group. Cancer Imaging 12(1):126–135

    Article  Google Scholar 

  18. Van den Abbeele AD, Badawi RD (2002) Use of positron emission tomography in oncology and its potential role to assess response to imatinib mesylate therapy in gastrointestinal stromal tumors (GIST). Eur J Cancer 38:S60–S65

    Article  Google Scholar 

  19. Choi H, Charnsangavej C, Faria SC et al (2007) Correlation of computed tomography and positron emission tomography in patients with metastatic gastrointestinal stromal tumor treated at a single institution with imatinib mesylate: proposal of new computed tomography response criteria. J Clin Oncol 25:1753–1759

    Article  Google Scholar 

  20. Stacchiotti S, Verderio P, Gronchi A et al (2012) Tumor response assessment by modified Choi criteria in localized high-risk soft tissue sarcoma treated with chemotherapy. Cancer 118(23):5857–5866

    Article  Google Scholar 

  21. Poveda A, del Muro XG, Martín-Broto J et al (2014) GEIS 2013 guidelines for gastrointestinal sarcomas (GIST). Cancer Chemother Pharmacol 74(5):883–898

    Article  CAS  Google Scholar 

  22. Prior J, Montemurro M, Orcurto MV et al (2008) Early prediction of response to sunitinib after imatinib failure by 18F fluorodeoxyglucose positron emission tomography in patients with gastrointestinal stromal tumor. J Clin Oncol 27:439–445

    Article  Google Scholar 

  23. Stroobants S, Goeminne J, Seegers M et al (2003) 18FDG-positron emission tomography for the early prediction of response in advanced soft tissue sarcoma treated with imatinib mesylate (Glivec). Eur J Cancer 39:2012–2020

    Article  CAS  Google Scholar 

  24. Gayed I, Vu T, Iyer R et al (2004) The role of 18F-FDG PET in staging and early prediction of response to therapy of recurrent gastrointestinal stromal tumors. J Nucl Med 45:17–21

    CAS  PubMed  Google Scholar 

  25. Tirumani SH, Jagannathan JP, Ramaiya NH et al (2013) Imatinib and beyond in gastrointestinal stromal tumors: a radiologist’s perspective. AJR Am J Roentgenol 201(4):801–810

    Article  Google Scholar 

  26. Desai J, Shankar S, Heinrich MC et al (2007) Clonal evolution of resistance to imatinib in patients with metastatic gastrointestinal stromal tumors. Clin Cancer Res 13:5398–5405

    Article  CAS  Google Scholar 

  27. Lassau N, Lamuraglia M, Chami L et al (2006) Gastro-intestinal stromal tumours treated with imatinib: monitoring response with contrast enhanced ultrasound. Am J Roentgenol 187:1267–1273

    Article  Google Scholar 

  28. Hayashida Y, Yakushiji T, Awai K et al (2006) Monitoring therapeutic responses of primary bone tumors by diffusion-weighted image: initial results. Eur Radiol 16:2637–2643

    Article  Google Scholar 

  29. Eilber F, Rosen G, Eckardt J et al (2001) Treatment-induced pathologic necrosis: a predictor of local recurrence and survival in patients receiving neoadjuvant therapy for high-grade extremity soft tissue sarcomas. J Clin Oncol 19:3203–3209

    Article  CAS  Google Scholar 

  30. Amini B, Jessop AC, Madewell JE et al (2015) Contemporary imaging of soft tissue sarcomas. J Surg Oncol 111(5):496–503

    Article  Google Scholar 

  31. Collin C, Godbold J, Hajdu S et al (1987) Localized extremity soft tissue sarcoma: an analysis of factors affecting survival. J Clin Oncol 5:601–612

    Article  CAS  Google Scholar 

  32. Gaynor JJ, Tan CC, Casper ES et al (1992) Refinement of clinicopathologic staging for localized soft tissue sarcoma of the extremity: a study of 423 adults. J Clin Oncol 10:1317–1329

    Article  CAS  Google Scholar 

  33. Evilevitch V, Weber WA, Tap WD et al (2008) Reduction of glucose metabolic activity is more accurate than change in size at predicting histopathologic response to neoadjuvant therapy in high-grade soft-tissue sarcomas. Clin Cancer Res 14:715–720

    Article  CAS  Google Scholar 

  34. Benz MR, Czernin J, Allen-Auerbach MS et al (2009) FDG-PET/CT imaging predicts histopathologic treatment responses after the initial cycle of neoadjuvant chemotherapy in high-grade soft-tissue sarcomas. Clin Cancer Res 15:2856–2863

    Article  CAS  Google Scholar 

  35. Dimitrakopoulou-Strauss A, Strauss LG, Egerer G et al (2010) Impact of dynamic 18F-FDG PET on the early prediction of therapy outcome in patients with high-risk soft-tissue sarcomas after neoadjuvant chemotherapy: a feasibility study. J Nucl Med 51:551–558

    Article  Google Scholar 

  36. Tateishi U, Kawai A, Chuman H et al (2011) PET/ CT allows stratification of responders to neoadjuvant chemotherapy for high-grade sarcoma: a prospective study. Clin Nucl Med 36:526–532

    Article  Google Scholar 

  37. Herrmann K, Benz M, Czernin J et al (2012) 18-FDG-PET/CT imaging as an early survival predictor in patients with primary high-grade soft tissue sarcomas undergoing neoadjuvant therapy. Clin Cancer Res 18:2024–2031

    Article  CAS  Google Scholar 

  38. Grosso F, Jones R, Demetri G et al (2007) Efficacy of trabectedin (ecteinascidin-743) in advanced pretreated myxoid liposarcomas: a retrospective study. Lancet Oncol 8:595–602

    Article  CAS  Google Scholar 

  39. Casali PG, Messina A, Stacchiotti S et al (2004) Imatinib mesylate in chordoma. Cancer 101:2086–2097

    Article  CAS  Google Scholar 

  40. Partovi S, Chalian M, Robbin MR et al (2014) Magnetic resonance/positron emission tomography (MR/PET) oncologic applications: bone and soft tissue sarcoma. Semin Roentgenol 49(4):345–352

    Article  Google Scholar 

  41. Vanel D, Shapeero LG, De Baere T et al (1994) MR imaging in the follow up of malignant and aggressive soft tissue tumors: results of 511 examinations. Radiology 190:263–268

    Article  CAS  Google Scholar 

  42. Panicek D, Schwartz L (1999) MR imaging of bone marrow in patients with musculoskeletal tumors. Sarcoma 3:37–41

    Article  CAS  Google Scholar 

  43. Joensuu H, Martin-Broto J, Maki RG et al (2015) Follow-up strategies for patients with gastrointestinal stromal tumour treated with or without adjuvant imatinib after surgery. Eur J Cancer 51(12):1611–1617

    Article  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Bioclinic Oncology Unit, Thessaloniki, Greece

    Ioannis P. Boukovinas

Authors
  1. Ioannis P. Boukovinas
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Ioannis P. Boukovinas .

Editor information

Editors and Affiliations

  1. School of Medicine, National and Kapodistrian, University of Athens, Athens, Greece

    Athanasios D. Gouliamos

  2. Imaging Department, Hygeia and Mitera Hospitals, Athens, Greece

    John A. Andreou

  3. Medical Oncologist, Head, Medical Oncology Department, Hygeia Hospital, Athens, Greece

    Paris A. Kosmidis

Rights and permissions

Reprints and permissions

Copyright information

© 2018 Springer International Publishing AG, part of Springer Nature

About this chapter

Check for updates. Verify currency and authenticity via CrossMark

Cite this chapter

Boukovinas, I.P. (2018). Clinical Implications of Soft Tissue Sarcomas. In: Gouliamos, A., Andreou, J., Kosmidis, P. (eds) Imaging in Clinical Oncology. Springer, Cham. https://doi.org/10.1007/978-3-319-68873-2_13

Download citation

  • DOI: https://doi.org/10.1007/978-3-319-68873-2_13

  • Published:

  • Publisher Name: Springer, Cham

  • Print ISBN: 978-3-319-68872-5

  • Online ISBN: 978-3-319-68873-2

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation